RxDoctor Payments Data

Arvinder Bir, MD

Family Medicine · Rancho Mirage, CANPI 1487629564

Payments from drug & device makers

$13,567in general payments, 2019–2025

Across 390 payments — averaging $34.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Amgen$767
  • GSK$703
  • Novartis$577
  • Daiichi Sankyo Inc.$501
  • Johnson & Johnson$330
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$6,666100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,567 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$344,570
Medicare patients
373
Services billed
6,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$60,982
FarxigaDapagliflozin Propanediol51$46,138
OzempicSemaglutide42$44,760
MounjaroTirzepatide16$25,942
JardianceEmpagliflozin13$17,346
JanuviaSitagliptin Phosphate12$14,568
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,270
XareltoRivaroxaban11$12,512
Levothyroxine Sodium223$4,447
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,950
Atorvastatin Calcium261$2,471
Valsartan94$2,352
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen65$2,203
Gabapentin88$2,144
Albuterol Sulfate HfaAlbuterol Sulfate75$2,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$289$60,98258 claims
AstraZenecaFarxiga$220$46,13851 claims
Novo NordiskOzempic$114$44,76042 claims
Lilly USA, LLCMounjaro$181$25,94216 claims
Boehringer IngelheimJardiance$228$17,34613 claims
MerckJanuvia$37$14,56812 claims
GSKTrelegy Ellipta$703$13,27015 claims
Johnson & JohnsonXarelto$330$12,51211 claims
AbbVieSynthroid$7,115$88919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →